Search by

Ajinomoto Bio-Pharma Services

Company Headquarters

11040 Roselle Street , San Diego, CA, 92121, US

Driving Directions Phone: View Phone Fax: View Fax

Request more information from Ajinomoto Bio-Pharma Services

Categories from Ajinomoto Bio-Pharma Services

Infographics

Working with Lipid Nanoparticle Based Drugs (LNPs) and Other Complex Formulations

If you are considering an LNP-based formulation or another complex drug, here are several points to consider to make the process more efficient.

Released By Ajinomoto Bio-Pharma Services

Literature / Brochures

Aji Bio-Pharma Corporate Brochure

As a member of the Ajinomoto Group, we offer an extensive global reach with facilities in Belgium, United States, Japan, and India.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

How To Select The Ideal HPAPI Manufacturing Partner

To ensure safety during HPAPI production, manufacturers must have the knowledge to effectively use containment and design high-quality equipment.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

To GMP Or Not To GMP? That Is The (Plasmid) Question

How can you maintain a manageable budget while procuring a high-quality plasmid supply?

Released By Ajinomoto Bio-Pharma Services

Sponsored Content

Leveraging CDMO’s in Pharma’s Drive Towards Net Zero

The push to reduce carbon emissions across some of the most energy-intensive industries has created new complexities for many companies.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

Identifying Sustainable Pathways Toward Oligonucleotide Therapeutics

After nearly 50 years of research and development, oligonucleotide therapeutics are starting to make their mark on the pharmaceutical scene.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

5 ADC Manufacturing Challenges You Need To Know

Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

Simplifying Recombinant Protein Production: Breaking Down the Corynex Protein Expression System

The rise of biologics is having a dramatic impact on how physicians treat many serious and chronic illnesses.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

Critical Factors of Fill Finish Manufacturing For Biologics

The bulk drug substance, formulation, and sterile filtering and filling of the final drug product all require special handling procedures.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

Is Your Complex Formulation Process Set Up for Success?

Often, the implementation of specialized equipment and/or processes is necessary to ensure successful formulation.

Released By Ajinomoto Bio-Pharma Services

White Papers / Tech Papers

Preparing for Your CDMO Selection Process

Finding the CDMO that is right for your company and project can be a daunting task, particularly if this is your first time outsourcing.

Released By Ajinomoto Bio-Pharma Services

News Releases

Biologics candidate enters clinical trials for first time using CORYNEX® Protein Expression System

San Diego, October 4, 2016 – Ajinomoto Althea, Inc. (“Althea”) announced that a biologics candidate developed by a Japanese global pharmaceutical company and manufactured at Ajinomoto Althea using CORYNEX® Protein Expression System, has entered phase I clinical trials. The CORYNEX® system of Ajinomoto Co., Inc. (“Ajinomoto Co.”) is a proprietary protein expression platform that combines […]

Released By Ajinomoto Bio-Pharma Services

News Releases

Althea Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies

SAN DIEGO, CA, May 17, 2016 — Ajinomoto Althea Inc., a leading provider of biotherapeutic contract development and manufacturing services, today announced that the United States Patent and Trademark Office has issued US Patent 9,310,379 covering methods to crystallize monoclonal antibodies for the purpose of scale up and cGMP manufacturing for therapeutic use.  The patented […]

Released By Ajinomoto Bio-Pharma Services

News Releases

Ajinomoto Althea Launches Process and Analytical Development Services for Antibody Drug Conjugates

SAN DIEGO – December 10th, 2015 — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs). The new facility is located in close proximity to existing Althea […]

Released By Ajinomoto Bio-Pharma Services

News Releases

Ajinomoto Althea Expands Its Capacity of Fill Finish Manufacturing with Addition of Second Shift

SAN DIEGO – March 15, 2016 — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biologics contract development and manufacturing services, announced today it is expanding the capacity of its Fill and Finish operations through the addition of a second manufacturing shift. Althea’s contract manufacturing business has experienced exceptionally strong growth driven by biotech companies […]

Released By Ajinomoto Bio-Pharma Services

News Releases

Ajinomoto Althea, Inc. Awarded California Competes Tax Credit

Last week, Ajinomoto Althea, Inc. (“Althea”) was awarded the California Competes Tax Credit by the California Governor’s Office of Business and Economic Development (“GO-Biz”). The $2,000,000 income tax credit was granted because of Althea’s continued commitment to grow and invest in its California-based operations. The Althea award was the largest granted to a San Diego […]

Released By Ajinomoto Bio-Pharma Services

News Releases

Ajinomoto Althea, Inc Receives European GMP Certification for Commercial Aseptic Filling and Testing

SAN DIEGO – [6.16.15] — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate from the Health Products Regulatory Authority (HPRA) for commercial aseptic filling and testing. The HPRA conducted a five day on-site inspection which commenced on February […]

Released By Ajinomoto Bio-Pharma Services

News Releases

Althea’s New Drug Formulation Technology Gains Attention from Two More Top Pharmaceutical Companies

SAN DIEGO – March 31, 2015 — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services, announced today that it has added two more top pharmaceutical companies to its growing list of partners in developing and manufacturing cGMP-produced crystal based drug products using Althea’s Crystalomics® drug delivery technology. With these […]

Released By Ajinomoto Bio-Pharma Services

Related Content